Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Because the evidence of the importance of HER3 is accumulating, incr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-07, Vol.27 (13), p.3528-3539
Hauptverfasser:	Haikala, Heidi M, Jänne, Pasi A
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Line, Tumor Drug Resistance, Neoplasm - genetics ErbB Receptors - genetics Humans Receptor, ErbB-3 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	3539
container_issue	13
container_start_page	3528
container_title	Clinical cancer research
container_volume	27
creator	Haikala, Heidi M Jänne, Pasi A
description	HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Because the evidence of the importance of HER3 is accumulating, increased amounts of preclinical and clinical trials with HER3-targeting agents are emerging. In this review article, we discuss the most recent HER3 biology in tumorigenic events and drug resistance and provide an overview of the current and emerging strategies to target HER3.
doi_str_mv	10.1158/1078-0432.CCR-20-4465
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2491943444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2491943444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-54a4a11e72dde6ec4b39bbf0276c1f8f3b408595f03d13515a9483dfdba6ea733</originalsourceid><addsrcrecordid>eNo9kE1Lw0AQhhdRbK3-BGWPXlL3YzYf3mxobaEglHrwtGySXRtJsnU3KfTfm9DW07wMzzsDD0KPlEwpFfELJVEcEOBsmqabgJEAIBRXaEyFiALOQnHd5wszQnfe_xBCgRK4RSPOQxJzGo_RfLsrXXvEX1o5j63By_mGv-KFszWeKV_meFbayn4fcWvxdqed2uuu7derptXuoJu2tI2_RzdGVV4_nOcEfS7m23QZrD_eV-nbOsiBsTYQoEBRqiNWFDrUOWQ8yTJDWBTm1MSGZ0BikQhDeEG5oEIlEPPCFJkKtYo4n6Dn0929s7-d9q2sS5_rqlKNtp2XDBKaAAeAHhUnNHfWe6eN3LuyVu4oKZGDQTnYkYMd2RuUjMjBYN97Or_osloX_62LMv4HfntrMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2491943444</pqid></control><display><type>article</type><title>Thirty Years of HER3: From Basic Biology to Therapeutic Interventions</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Haikala, Heidi M ; Jänne, Pasi A</creator><creatorcontrib>Haikala, Heidi M ; Jänne, Pasi A</creatorcontrib><description>HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Because the evidence of the importance of HER3 is accumulating, increased amounts of preclinical and clinical trials with HER3-targeting agents are emerging. In this review article, we discuss the most recent HER3 biology in tumorigenic events and drug resistance and provide an overview of the current and emerging strategies to target HER3.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-20-4465</identifier><identifier>PMID: 33608318</identifier><language>eng</language><publisher>United States</publisher><subject>Cell Line, Tumor ; Drug Resistance, Neoplasm - genetics ; ErbB Receptors - genetics ; Humans ; Receptor, ErbB-3 - genetics</subject><ispartof>Clinical cancer research, 2021-07, Vol.27 (13), p.3528-3539</ispartof><rights>2021 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-54a4a11e72dde6ec4b39bbf0276c1f8f3b408595f03d13515a9483dfdba6ea733</citedby><cites>FETCH-LOGICAL-c422t-54a4a11e72dde6ec4b39bbf0276c1f8f3b408595f03d13515a9483dfdba6ea733</cites><orcidid>0000-0002-8465-8568</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33608318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haikala, Heidi M</creatorcontrib><creatorcontrib>Jänne, Pasi A</creatorcontrib><title>Thirty Years of HER3: From Basic Biology to Therapeutic Interventions</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Because the evidence of the importance of HER3 is accumulating, increased amounts of preclinical and clinical trials with HER3-targeting agents are emerging. In this review article, we discuss the most recent HER3 biology in tumorigenic events and drug resistance and provide an overview of the current and emerging strategies to target HER3.</description><subject>Cell Line, Tumor</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>ErbB Receptors - genetics</subject><subject>Humans</subject><subject>Receptor, ErbB-3 - genetics</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1Lw0AQhhdRbK3-BGWPXlL3YzYf3mxobaEglHrwtGySXRtJsnU3KfTfm9DW07wMzzsDD0KPlEwpFfELJVEcEOBsmqabgJEAIBRXaEyFiALOQnHd5wszQnfe_xBCgRK4RSPOQxJzGo_RfLsrXXvEX1o5j63By_mGv-KFszWeKV_meFbayn4fcWvxdqed2uuu7derptXuoJu2tI2_RzdGVV4_nOcEfS7m23QZrD_eV-nbOsiBsTYQoEBRqiNWFDrUOWQ8yTJDWBTm1MSGZ0BikQhDeEG5oEIlEPPCFJkKtYo4n6Dn0929s7-d9q2sS5_rqlKNtp2XDBKaAAeAHhUnNHfWe6eN3LuyVu4oKZGDQTnYkYMd2RuUjMjBYN97Or_osloX_62LMv4HfntrMA</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Haikala, Heidi M</creator><creator>Jänne, Pasi A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8465-8568</orcidid></search><sort><creationdate>20210701</creationdate><title>Thirty Years of HER3: From Basic Biology to Therapeutic Interventions</title><author>Haikala, Heidi M ; Jänne, Pasi A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-54a4a11e72dde6ec4b39bbf0276c1f8f3b408595f03d13515a9483dfdba6ea733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cell Line, Tumor</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>ErbB Receptors - genetics</topic><topic>Humans</topic><topic>Receptor, ErbB-3 - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haikala, Heidi M</creatorcontrib><creatorcontrib>Jänne, Pasi A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haikala, Heidi M</au><au>Jänne, Pasi A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thirty Years of HER3: From Basic Biology to Therapeutic Interventions</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>27</volume><issue>13</issue><spage>3528</spage><epage>3539</epage><pages>3528-3539</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Because the evidence of the importance of HER3 is accumulating, increased amounts of preclinical and clinical trials with HER3-targeting agents are emerging. In this review article, we discuss the most recent HER3 biology in tumorigenic events and drug resistance and provide an overview of the current and emerging strategies to target HER3.</abstract><cop>United States</cop><pmid>33608318</pmid><doi>10.1158/1078-0432.CCR-20-4465</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-8465-8568</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1078-0432
ispartof	Clinical cancer research, 2021-07, Vol.27 (13), p.3528-3539
issn	1078-0432 1557-3265
language	eng
recordid	cdi_proquest_miscellaneous_2491943444
source	MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects	Cell Line, Tumor Drug Resistance, Neoplasm - genetics ErbB Receptors - genetics Humans Receptor, ErbB-3 - genetics
title	Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T23%3A55%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thirty%20Years%20of%20HER3:%20From%20Basic%20Biology%20to%20Therapeutic%20Interventions&rft.jtitle=Clinical%20cancer%20research&rft.au=Haikala,%20Heidi%20M&rft.date=2021-07-01&rft.volume=27&rft.issue=13&rft.spage=3528&rft.epage=3539&rft.pages=3528-3539&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-20-4465&rft_dat=%3Cproquest_cross%3E2491943444%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2491943444&rft_id=info:pmid/33608318&rfr_iscdi=true